Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 4/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15327063 | 0.98 | FEN1 (0.49) | FEN1HCRTR1HCRTR2GRM5CREBBP | |
| SCHEMBL15338817 | 0.85 | NAMPT (0.52) | HCRTR1HCRTR2GRM5CREBBPNAMPT | |
| SCHEMBL9977896 | 0.84 | CREBBP (0.51) | FEN1CREBBPMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL15326968 | 0.82 | CREBBP (0.50) | FEN1CREBBPMAPTL3MBTL1 | |
| SCHEMBL9977865 | 0.80 | HCRTR1 (0.53) | HCRTR1HCRTR2GRM5CREBBPNAMPT | |
| SCHEMBL30574243 | 0.79 | ALOX5AP (0.42) | HCRTR1HCRTR2GRM5 | |
| SCHEMBL15604646 | 0.78 | HCRTR1 (0.52) | HCRTR1HCRTR2GRM5NAMPT | |
| Hydrochloric Acid SCHEMBL16648614 | 0.77 | HCRTR1 (0.51) | HCRTR1HCRTR2GRM5NAMPT | |
| SCHEMBL15327002 | 0.77 | HCRTR1 (0.63) | HCRTR1HCRTR2NAMPT | |
| SCHEMBL16561338 | 0.76 | MKNK1 (0.50) | FEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| WO-2012081692-A1 | PYRAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | HCRTR1, HCRTR2, NPY4R | FEN1 4849/4885HCRTR1 1/4885HCRTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.